PLoS ONE (Jan 2017)

Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe.

  • Mufuta Tshimanga,
  • Batsirai Makunike-Chikwinya,
  • Tonderayi Mangwiro,
  • Patricia Tapiwa Gundidza,
  • Pesanai Chatikobo,
  • Vernon Murenje,
  • Amy Herman-Roloff,
  • Peter H Kilmarx,
  • Marrianne Holec,
  • Gerald Gwinji,
  • Owen Mugurungi,
  • Munyaradzi Murwira,
  • Sinokuthemba Xaba,
  • Scott Barnhart,
  • Caryl Feldacker

DOI
https://doi.org/10.1371/journal.pone.0189146
Journal volume & issue
Vol. 12, no. 12
p. e0189146

Abstract

Read online

MethodsWe aimed to determine if the adverse event (AE) rate was non-inferior to an AE rate of 2%, a rate considered the global standard of MC safety. Study procedures, AE definitions, and study staff were unchanged from previous PrePex Zimbabwe trials. After PrePex placement and removal, weekly visits assessed wound healing. Men returned on Day 90. Safety was defined as occurrence of moderate and serious clinical AEs. Efficacy was defined as ability to reach the endpoint of complete circumcision.ResultsAmong 400 healthy, HIV-positive, consenting adults, median age was 40 years (IQR: 34, 46); 79.5% in WHO stage 2; median CD4 was 336.5c/μl (IQR: 232, 459); 337 (85%) on anti-retroviral therapy. Among 385 (96%) observed completely healed, median days to complete healing was 42 (IQR: 35-49). There was no association between time to healing and CD4 (p = 0.66). Four study-related severe AEs and no moderate AEs were reported: severe/moderate AE rate of 1.0% (95% CI: 0.27% to 2.5). This was non-inferior to 2% AEs (p = 0.0003). All AEs were device displacements resulting in surgical MC and, subsequently, complete healing.ConclusionMale circumcision among healthy, HIV-positive men using PrePex is safe and effective. Reducing the barrier of HIV testing while improving counseling for safer sex practices among all MC clients could increase MC uptake and avert more HIV infections.